Nancy King to Ethics, Research
This is a "connection" page, showing publications Nancy King has written about Ethics, Research.
Connection Strength
1.145
-
King NM, Iltis AS. Introduction: research ethics: reexamining key concerns. J Law Med Ethics. 2012; 40(4):865-6.
Score: 0.417
-
Andrews JE, Moore JB, Weinberg RB, Sissine M, Gesell S, Halladay J, Rosamond W, Bushnell C, Jones S, Means P, King NMP, Omoyeni D, Duncan PW. Ensuring respect for persons in COMPASS: a cluster randomised pragmatic clinical trial. J Med Ethics. 2018 08; 44(8):560-566.
Score: 0.162
-
Macklin R, Shepherd L, Dreger A, Asch A, Baylis F, Brody H, Churchill LR, Coleman CH, Cowan E, Dolgin J, Downie J, Dresser R, Elliott C, Epright MC, Feder EK, Glantz LH, Grodin MA, Hoffman W, Hoffmaster B, Hunter D, Iltis AS, Kahn JD, King NM, Kraft R, Kukla R, Leavitt L, Lederer SE, Lemmens T, Lindemann H, Marshall MF, Merz JF, Miller FH, Mohrmann ME, Morreim H, Nass M, Nelson JL, Noble JH, Reis E, Reverby SM, Silvers A, Sousa AC, Spece RG, Strong C, Swazey JP, Turner L. The OHRP and SUPPORT--another view. N Engl J Med. 2013 Jul 11; 369(2):e3.
Score: 0.115
-
Henderson GE, Juengst ET, King NM, Kuczynski K, Michie M. What research ethics should learn from genomics and society research: lessons from the ELSI Congress of 2011. J Law Med Ethics. 2012; 40(4):1008-24.
Score: 0.104
-
Hall MA, King NM, Perdue LH, Hilner JE, Akolkar B, Greenbaum CJ, McKeon C. Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium. Clin Trials. 2010; 7(1 Suppl):S33-45.
Score: 0.091
-
Weinfurt KP, Hall MA, King NM, Friedman JY, Schulman KA, Sugarman J. Disclosure of financial relationships to participants in clinical research. N Engl J Med. 2009 Aug 27; 361(9):916-21.
Score: 0.089
-
Henderson GE, Easter MM, Zimmer C, King NM, Davis AM, Rothschild BB, Churchill LR, Wilfond BS, Nelson DK. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med. 2006 Jan; 62(1):239-53.
Score: 0.066
-
Henderson GE, Davis AM, King NM. Vulnerability to influence: a two-way street. Am J Bioeth. 2004; 4(3):50-2; discussion W32.
Score: 0.060
-
Hall MA, Friedman JY, King NM, Weinfurt KP, Schulman KA, Sugarman J. Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. Acad Med. 2010 Oct; 85(10):1554-6.
Score: 0.024
-
Kipnis K, King NM, Nelson RM. An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial. Am J Bioeth. 2006 May-Jun; 6(3):18-21.
Score: 0.018